"AMBS" - Current market cap of $26M. Zack's analyst Jason Napadano says it should be $90,000,000 and rates the stock a "BUY".
Currently trading at a nickle. Jason's target is .20.
Potential deals with Becton Dickinson and Novartis.
Read the recent Yahoo news.
Follow the company on Twitter: @AmarantusBio .... 8,594 followers
Buy a few shares today and recoup some DNDN losses.
The company's drug, MANF, already has one orphan indication for Retinitis Pigmentosa. It also has another one to be announced soon. Possible treatment for Alzheimer's and Parkinson's.
Research Amarantus Bioscience.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the comapny's advisory board.